The Prognostic and Predictive Value of EGFR and HER-2 in Advanced Non-small Cell Lung Cancer Patients Who Are Treated with Cisplatin and Paclitaxel
Journal of Lung Cancer
; : 13-20, 2009.
Article
Dans Ko
| WPRIM
| ID: wpr-54357
Responsable en Bibliothèque :
WPRO
ABSTRACT
PURPOSE:
Although both platinum-based drugs and third-generation drugs are commonly used as first-line therapy for patients with advanced, unresectable non-small cell lung cancer, their effectiveness and clinical outcomes vary. We investigated whether epidermal growth factor receptor (EGFR) and HER-2 were correlated with the chemoresponse and survival after treatment with a cisplatin plus paclitaxel regimen. MATERIALS ANDMETHODS:
Forty-nine tumors were analyzed by chromogenic in situ hybridization (CISH) for EGFR and HER-2 gene amplification.RESULTS:
Twenty-eight patients (57%) achieved a partial response (PR), 13 (27%) showed stable disease (SD) and 8 (16%) had progressive disease (PD). EGFR and HER-2 amplification was identified in 43% and 57% of the tumors, respectively. EGFR amplification revealed no association with either a chemoresponse or survival, whereas HER-2 was amplified more frequently in the patients with PD (88% vs. 54%, respectively, p=0.06) and in the patients with shorter survival (12 months vs. 20 months respectively, p=0.027).CONCLUSION:
The evaluation of HER-2 gene amplification is a promising approach for identifying those patients who are most likely to benefit from combination chemotherapy with cisplatin and paclitaxel
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Cisplatine
/
Paclitaxel
/
Hybridation in situ
/
Carcinome pulmonaire non à petites cellules
/
Gènes erbB-2
/
Association de médicaments
/
Récepteurs ErbB
Type d'étude:
Prognostic_studies
Limites du sujet:
Humans
langue:
Ko
Texte intégral:
Journal of Lung Cancer
Année:
2009
Type:
Article